Predictive Biomarkers of Bacillus Calmette-Guérin Immunotherapy Response in Bladder Cancer: Where Are We Now?
Advances in Urology · 2012 · 2012 · 1-17
DOI: 10.1155/2012/232609 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Urology, 2012. Verfasst von Luís Lima und 3 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, 4200-072 Porto, Portugal. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: Fundação para a Ciência e Tecnologia, European Social Fund.
Abstract (Originalsprache)
The most effective therapeutic option for managing nonmuscle invasive bladder cancer (NMIBC), over the last 30 years, consists of intravesical instillations with the attenuated strain Bacillus Calmette-Guérin (the BCG vaccine). This has been performed as an adjuvant therapeutic to transurethral resection of bladder tumour (TURBT) and mostly directed towards patients with high-grade tumours, T1 tumours, and in situ carcinomas. However, from 20% to 40% of the patients do not respond and frequently present tumour progression. Since BCG effectiveness is unpredictable, it is important to find consistent biomarkers that can aid either in the prediction of the outcome and/or side effects development. Accordingly, we conducted a systematic critical review to identify the most preeminent predictive molecular markers associated with BCG response. To the best of our knowledge, this is the first review exclusively focusing on predictive biomarkers for BCG treatment outcome. Using a specific query, 1324 abstracts were gathered, then inclusion/exclusion criteria were applied, and finally 87 manuscripts were included. Several molecules, including CD68 and genetic polymorphisms, have been identified as promising surrogate biomarkers. Combinatory analysis of the candidate predictive markers is a crucial step to create a predictive profile of treatment response.
Autor:innen und Institutionen
- Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, 4200-072 Porto, Portugal.
Förderung
- Fundação para a Ciência e Tecnologia
- European Social Fund
Zitieren
APA
Lima, L., Dinis-Ribeiro, M., Longatto-Filho, A., & Santos, L. (2012). Predictive Biomarkers of Bacillus Calmette-Guérin Immunotherapy Response in Bladder Cancer: Where Are We Now?. Advances in Urology, 2012, 1-17. https://doi.org/10.1155/2012/232609
Vancouver
Lima L, Dinis-Ribeiro M, Longatto-Filho A, Santos L. Predictive Biomarkers of Bacillus Calmette-Guérin Immunotherapy Response in Bladder Cancer: Where Are We Now?. Advances in Urology. 2012;2012:1-17. doi:10.1155/2012/232609
BibTeX
@article{Lima2012,
author = {Lima, Luís and Dinis-Ribeiro, Mário and Longatto-Filho, Adhemar and Santos, Lúcio},
title = {Predictive Biomarkers of Bacillus Calmette-Guérin Immunotherapy Response in Bladder Cancer: Where Are We Now?},
journal = {Advances in Urology},
year = {2012},
volume = {2012},
pages = {1--17},
doi = {10.1155/2012/232609}
}
EUVIMED